0.681
price down icon7.21%   -0.053
 
loading
Biofrontera Inc stock is traded at $0.681, with a volume of 193.41K. It is down -7.21% in the last 24 hours and down -18.92% over the past month. Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
See More
Previous Close:
$0.734
Open:
$0.74
24h Volume:
193.41K
Relative Volume:
0.08
Market Cap:
$3.83M
Revenue:
$34.07M
Net Income/Loss:
$-20.13M
P/E Ratio:
-0.0398
EPS:
-17.1162
Net Cash Flow:
$-24.90M
1W Performance:
-16.95%
1M Performance:
-18.92%
6M Performance:
-36.35%
1Y Performance:
-81.19%
1-Day Range:
Value
$0.6513
$0.7599
1-Week Range:
Value
$0.6513
$1.0099
52-Week Range:
Value
$0.61
$4.04

Biofrontera Inc Stock (BFRI) Company Profile

Name
Name
Biofrontera Inc
Name
Phone
781-245-1325
Name
Address
120 PRESIDENTIAL WAY,, WOBURN
Name
Employee
85
Name
Twitter
Name
Next Earnings Date
2024-11-13
Name
Latest SEC Filings
Name
BFRI's Discussions on Twitter

Compare BFRI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BFRI 0.6809 3.83M 34.07M -20.13M -24.90M -17.12
ZTS 176.38 79.52B 9.15B 2.43B 2.31B 4.92
TAK 13.54 43.13B 30.27B 1.93B 3.45B 0.444
HLN 9.425 42.57B 14.26B 1.55B 0 0.3327
TEVA 16.47 18.56B 16.77B -959.00M 1.37B -2.00
VTRS 13.02 15.37B 15.24B -646.50M 1.88B 1.53

Biofrontera Inc Stock (BFRI) Latest News

pulisher
Nov 16, 2024

Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 16, 2024
pulisher
Nov 15, 2024

Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 13, 2024

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 06, 2024

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com

Nov 06, 2024
pulisher
Nov 01, 2024

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

Biofrontera Announces Promising Phase 3 Study Results - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera reports breakthrough in skin cancer treatment - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire

Oct 31, 2024
pulisher
Oct 23, 2024

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance

Oct 23, 2024
pulisher
Oct 15, 2024

Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 14, 2024

Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India

Oct 14, 2024
pulisher
Oct 14, 2024

Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire

Oct 14, 2024
pulisher
Oct 14, 2024

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

Oct 14, 2024
pulisher
Oct 08, 2024

BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 08, 2024
pulisher
Oct 07, 2024

Mass. Biotech Receives FDA Approval - Streetwise Reports

Oct 07, 2024
pulisher
Oct 07, 2024

Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India

Oct 07, 2024
pulisher
Oct 07, 2024

What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan

Oct 07, 2024
pulisher
Oct 04, 2024

BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Oct 04, 2024
pulisher
Oct 04, 2024

Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 04, 2024
pulisher
Oct 04, 2024

Biotech Stocks Facing FDA Decision In October 2024 - RTTNews

Oct 04, 2024
pulisher
Oct 03, 2024

Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com

Oct 03, 2024
pulisher
Oct 02, 2024

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Oct 02, 2024
pulisher
Oct 02, 2024

Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023) - Yahoo Finance

Oct 02, 2024
pulisher
Oct 01, 2024

Five PDUFA dates on FDA’s October agenda - BioCentury

Oct 01, 2024
pulisher
Oct 01, 2024

Photodynamic Therapy Market Share, Trends, Size, Major Players And Forecast To 2033 - WhaTech

Oct 01, 2024
pulisher
Sep 28, 2024

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St

Sep 28, 2024
pulisher
Sep 25, 2024

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Taking on analysts’ expectations and winning: Biofrontera Inc (BFRI) - SETE News

Sep 24, 2024
pulisher
Sep 23, 2024

Trading Day Triumph: Biofrontera Inc (BFRI) Ends at 1.28, a 0.00 Surge/Plunge - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

A stock that deserves closer examination: Biofrontera Inc (BFRI) - US Post News

Sep 23, 2024
pulisher
Sep 20, 2024

Leidos Holdings, Inc. (NYSE:LDOS) Shares Sold by Tredje AP fonden - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Market Insight: Biofrontera Inc (BFRI)’s Notable Gain, Closing at 1.29 - The Dwinnex

Sep 19, 2024
pulisher
Sep 13, 2024

Taking the lead: Biofrontera Inc (BFRI) - SETE News

Sep 13, 2024
pulisher
Sep 12, 2024

Biofrontera Inc (BFRI) Stock: From Low to High in 52 Weeks - The InvestChronicle

Sep 12, 2024

Biofrontera Inc Stock (BFRI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$76.27
price down icon 0.72%
$13.38
price down icon 4.28%
$81.96
price down icon 1.77%
$58.72
price down icon 0.65%
$117.38
price up icon 0.26%
$12.79
price down icon 0.97%
Cap:     |  Volume (24h):